צמיחת הכנסות שנתית ב-12 החודשים האחרונים: Savara Pharma (SVRA)

Savara Inc. (SVRA) aims for dominance in the therapy of a rare lung condition through the launch of inhaled molgramostim in the US and Europe. Patent protection and the success of final tests ensure high profitability, while the year-over-year sales volume growth trajectory for the TTM confirms demand, where the value of 0.00 reflects this status. Specialization in orphan diseases creates a permanent niche with guaranteed income.
פילוחי נתונים אנליטיים מרוכזים עבור Savara (SVRA)

This indicator measures revenue dynamics over a rolling year, reflecting the actual pace of business expansion and its resilience to market cycles. By analyzing the Last Twelve Months (LTM) change in trading revenue, an investor can gauge the efficiency of Savara Inc. (SVRA) in the express logistics of orphan drugs, where the diversification of production sites across the US and Europe minimizes supply chain disruption risks and supports high margins.